# MobileODT

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mobileodt

- Industry: Medical Devices & Equipment
- Headquarters: Tel Aviv-Yafo, Israel
- Website: www.mobileodt.com
- Total disclosed funding: $11M
- Latest round: Series C (Aug 12, 2020)
- Investors on record: 4

## About

MobileODT Ltd. develops advanced diagnostic and treatment solutions for cervical cancer, notably the Eva Pro mini colposcope, enhancing healthcare providers' ability to conduct early detection and effective treatment protocols.Founded in 2012 and headquartered in Tel Aviv-Yafo, Israel, MobileODT Ltd. specializes in innovative cervical cancer diagnostic solutions. The company has completed a total of 8 funding deals, with the latest being a Grant of USD 2.3 mn from the National Cancer Institute on January 20, 2021, raising a total of USD 4.0 mn since its inception. The founder, David Levitz, has significant experience in healthcare technology innovation.MobileODT specializes in advanced diagnostic and treatment solutions for cervical cancer, focusing primarily on its core offering, the Eva Pro mini colposcope. This next-generation digital colposcope is designed for both magnified visualization and documentation, utilizing cutting-edge software capabilities powered by artificial intelligence. The device enables healthcare professionals to capture high-quality images of the cervix, facilitating immediate assessment and treatment of cervical abnormalities. MobileODT's product line also includes the ThermoGlide, which provides point-of-care thermocoagulation treatment with minimal patient discomfort, and the EVA SANE, a tool for streamlining sexual assault forensic examinations. These products are utilized by healthcare providers in various regions, including North America, Europe, and parts of Asia and Africa, addressing the pressing need for accessible cervical cancer screening and treatment solutions in diverse healthcare settings.MobileODT generates revenue through direct sales of its flagship products, including the Eva Pro mini colposcope and ThermoGlide, to healthcare facilities, clinics, and practitioners. The company operates on a direct-to-consumer model, engaging with healthcare providers who require advanced diagnostic tools for cervical health. Transaction structures typically involve one-time purchases for equipment, along with potential contracts for ongoing supplies or service agreements for software updates. Specific pricing plans for these products are established based on the complexity and functionality offered, enhancing the value provided to healthcare professionals. The company's strategic partnerships with healthcare institutions further support its revenue streams by facilitating broader adoption of its innovative solutions.MobileODT plans to leverage the recent Grant funding of USD 2.3 mn from the National Cancer Institute to further enhance its product offerings and expand market reach. The company is in the process of designing new products aimed at improving cervical cancer diagnostics and treatment outcomes. Additionally, MobileODT is targeting expansion into new markets, particularly in regions with emerging healthcare needs, by 2023, which aligns with its mission to increase the accessibility of cervical cancer care globally.

## Funding rounds

- Series C, Aug 12, 2020, $4M — OrbiMed Advisors, Tristel Solutions Ltd., Tara Health Foundation, Laerdal Medical AS
- Series B, Jul 5, 2017, $6.8M — OrbiMed Advisors, Tristel Solutions Ltd.

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- Tristel Solutions Ltd. — Series B, Series C
- Tara Health Foundation — Series C
- Laerdal Medical AS — Series C